Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer.

摘要: We carried out a meta-analysis to evaluate the benefit of epidermal growth factor-tyrosine kinase inhibitors (EGFR-TKI) over standard first-line platinum-based chemotherapy for metastatic non-small-cell lung cancer (NSCLC). Studies that were considered eligible included controlled prospective randomized phase III studies in patients with NSCLC stages IIIB or IV. These received EGFR-TKI; overall survival and progression-free (PFS) adequate data available calculate estimate hazard ratio (HR) confidence interval (CI) 95%. Eight identified compared EGFR-TKI versus treat 2962 patients. Patients receiving showed significantly longer PFS [HR=0.266 (95% CI=0.20-0.35), P<0.0001]. No significant difference [HR=0.946 CI=0.35-2.53), P=0.912] was observed between groups. The cumulative that, since 2011 (OPTIMAL study), arm statistically longer. Toxicity values greater than equal 3 most prevalent group skin rash, diarrhea, increased aminotransferase. treatment extends PFS, acceptable toxicities chemotherapy. Thus, they should be as first choice EGFR mutation.